Loading organizations...
Loading organizations...

Fulcrum Therapeutics: Biotech company developing small molecule therapies for genetically defined rare diseases, focused on gene regulation.
Founded in 2016 by Michael Green, Danny Reinberg, and Rudolf Jaenish, Fulcrum Therapeutics is a Cambridge, Massachusetts-based publicly traded biotechnology company that develops small molecule therapies to modulate gene regulation for treating genetically defined rare diseases. Initially backed by venture capital creator Third Rock Ventures with a $55 million Series A funding round, the drug development enterprise utilizes proprietary technology to identify targets addressing the root causes of gene mis-expression. The business focuses on creating transformative treatments for patients and caregivers in the rare disease community managing conditions with high unmet medical needs. Operating with a workforce of 55 employees, the organization maintains a public market enterprise value of $370,682,050. The company's executive leadership includes current president and chief executive officer Alex C. Sapir, who succeeded former chief executive officer Robert J. Gould following his March retirement.
Fulcrum Therapeutics has raised $135.0M across 2 funding rounds.
Fulcrum Therapeutics has raised $135.0M in total across 2 funding rounds.
Fulcrum Therapeutics has raised $135.0M in total across 2 funding rounds.
Fulcrum Therapeutics's investors include Foresite Capital, ARCH Venture Partners, Krishna Yeshwant, 6 Dimensions Capital, Casdin Capital, Fidelity Management & Research Company, Leerink Partners, NS Investments, Sanofi Ventures, Section 32, Third Rock Ventures.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies that modulate gene expression to treat genetically defined rare diseases, such as sickle cell disease (SCD).[1][2][4][6] Its lead program, pociredir, is in clinical trials for SCD, targeting the root causes of these conditions through an integrated, patient-driven approach using patient-derived cells, proprietary screening tools like FulcrumSeek, and biomarker strategies to create disease-modifying treatments.[2][3][4] The company serves patients and families facing high unmet needs in rare genetic disorders, solving problems like ineffective symptom management by restoring healthy gene function, with a mission to "pioneer therapies that rewrite the future for patients with genetically defined diseases."[1][2][6]
Fulcrum Therapeutics was founded in 2015 to address genetically defined rare diseases through gene expression modulation.[1] While specific founders are not detailed in available sources, the company's emergence reflects a response to the unmet need for therapies tackling disease root causes rather than symptoms, leveraging advances in data science, patient biology, and small-molecule drug discovery.[1][2] Early traction built on patient-inspired insights, with pivotal moments including partnerships with the SCD community and advancement of pociredir into clinical trials, humanizing its work through stories like those of patients Kadeem and Teonna.[3]
Fulcrum rides the trend of precision medicine in rare genetic diseases, where thousands of conditions have known genetic roots but few targeted therapies exist, amplified by advances in gene regulation, CRISPR, and patient-derived models.[1][2] Timing aligns with growing investment in biotech platforms addressing unmet needs in areas like SCD, supported by market forces such as rising demand for disease-modifying treatments and regulatory incentives for rare diseases.[3][4] It influences the ecosystem by prioritizing patient partnerships, advancing clinical programs like pociredir, and modeling biomarker-driven development that could accelerate therapies for similar disorders.[2][3]
Fulcrum's next milestones include advancing pociredir through SCD clinical trials and expanding its product engine to other genetically defined diseases, potentially yielding approvals that validate its gene modulation approach.[4] Trends like AI-enhanced drug discovery and expanded gene therapy access will shape its path, with its patient-centric model positioning it to influence biotech by setting standards for root-cause therapies in rare diseases. As a clinical-stage player backed by innovative science, Fulcrum exemplifies how targeted biotech can transform lives in high-need areas, tying back to its core mission of rewriting futures for genetically defined disease patients.[1][2][6]
Fulcrum Therapeutics has raised $135.0M across 2 funding rounds. Most recently, it raised $80.0M Series B in September 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2018 | $80.0M Series B | Foresite Capital | ARCH Venture Partners, Krishna Yeshwant, 6 Dimensions Capital, Casdin Capital, Fidelity Management & Research Company, Leerink Partners, NS Investments, Sanofi Ventures, Section 32 |
| Jul 19, 2016 | $55.0M Series A | Third Rock Ventures |